FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare

Pfizer gives Nektar $135M for Exubera settlement

Nektar Therapeutics got a consolation prize of $135 million from Pfizer--and a fresh shot at signing a new partner--to calm any upset feelings about Pfizer's abandonment of Exubera, a once mighty prospect in the world of inhalable diabetes therapies. In return, both parties are absolved of any further obligations for Exubera or the next-generation version of the therapy that Nektar has in Phase I. And if Nektar lines up a new partner, Pfizer has agreed to hand over any rights it has in the two products.

- check out Pfizer's release
- here's the report on Nektar from RTT News

Related Articles:
Pfizer kills off Exubera, hunts for deals. Report
Exubera becoming a big disappointment for Pfizer. Report
UK: Exubera not worth the price. Report
FDA approves Pfizer's inhaled insulin. Report

More stories about Nektar Iherapeutics   insulin   Exubera   FDA   Pfizer  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

What is 23 + 74?
To combat spam, please solve the math question above.